Alex Telford Profile picture
Jul 7, 2023 9 tweets 4 min read Read on X
Many of the drugs discovered by Paul Janssen and his team at Janssen Pharmaceutica have a piperidine ring at the centre. The reason why is a good lesson about how effective innovation happens in practice🧵
When Janssen was starting out he had limited resources and needed a way to make compounds quickly, simply, and cheaply. Rapidly swapping out "heads" and "tails" on either side of a central piperidine was one way his team figured out how to do this
These days piperidines are common structural motifs in approved pharmaceuticals. But why did Janssen pick piperidines early on?

One reason is that they were fairly easy to work with given the medicinal chemistry tools available at the time
Another reason is that one of Janssen's early goals was to find more potent painkillers, and his initial strategy for doing so was to start with the widely used synthetic opioid meperidine (pethidine) and modify the head and tail regions to improve its analgesic properties
Although structurally similar, haloperidol, fentanyl, and loperamide have strikingly different effects. Each was discovered through hypothesis-driven iterative trial and error combined with a willingness to investigate unexpected interesting findings
One of Janssen's iterations on meperidine, R-951, was serendipitously found to have a primarily tranquilizing rather than analgesic effect in mice, and optimizing it led to the discovery of the first-generation antipsychotic haloperidol
One of the side effects of opioid use is constipation. Loperamide, an antidiarrheal better known as Imodium, was discovered through iterative attempts to engineer out the central nervous system activity of opioids while retaining the antidiarrheal activity
One of the reasons Janssen was able to innovate so effectively and bring >70 drugs to market was because he got in to a new field early, found a rapid and cheap way of iterating and screening new compounds, and maintained an openness to explore promising serendipitous findings
I adapted this thread from "Breakthrough: The Discovery of Modern Medicines at Janssen", an excellent 1989 book about Paul Janssen's life and discoveries

amazon.com/Breakthrough-D…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Alex Telford

Alex Telford Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Atelfo

Aug 19, 2025
A thread about the unreasonable effectiveness of writing on the internet, or how I got 8.6 million dollars from a blog post
About two years ago, I left my job in biotech consulting on a whim. GPT-3 and 4 had got me excited about LLMs; I knew they would be important, but I didn't yet know how best to apply them to the problems I was familiar with. I wanted some space to experiment
My intuition at the time was that LLMs would be a powerful tool to accelerate knowledge work in the life sciences industry where so much of the work is unstructured information synthesis and preparation of complex documents (manuscripts, INDs, etc.) -- but what was the right UX?
Read 11 tweets
Dec 23, 2023
In 1953, aged 27, Paul Janssen set up a pharma company that would grow into one of the world's largest. Over his career, Janssen and his team brought >70 drugs to market.

Yet, today's drug hunters are likely to retire before discovering even one new medicine. What changed?🧵 Image
For one, Janssen had good timing. Since Janssen started his career, biopharma R&D efficiency has followed a long-term declining trajectory (@JackScannell13 called the trend "Eroom's law"). But what's behind the decline? Image
Increasingly stringent regulation explain part of it. But the bigger reason is that we already have many good (and cheap!) treatments. New drugs need to show benefit on top of existing ones, or they need to target niche populations — this makes trials expensive and failure-prone Image
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(